Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Historical Valuation Ratios (Summary)

Cytokinetics Inc., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Price to earnings (P/E) — — — — — — — — — — — — — — — — — — — — — — —
Price to operating profit (P/OP) — — — — — — — — — — — — — — — — — — — — — — —
Price to sales (P/S) 455.70 305.78 38.47 43.37 24.10 32.28 50.13 42.19 159.98 45.97 29.69 23.86 22.07 81.16 42.16 32.88 21.30 22.26 14.99 10.47 — — —
Price to book value (P/BV) — — — — — 43.79 28.04 12.19 13.84 161.16 25.62 11.75 8.01 — — — — — 154.23 12.72 7.48 5.16 4.73

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Cytokinetics Inc. P/S ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Price to Earnings (P/E)

Cytokinetics Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 98,053,647 95,997,998 95,640,600 95,161,391 94,631,001 94,144,097 85,652,213 84,856,037 83,882,953 83,512,670 71,738,143 71,110,576 70,779,023 70,504,701 59,469,525 59,450,437 59,081,899 58,678,894 57,721,286 54,888,369 54,710,900 54,627,997 54,197,546
Selected Financial Data (US$)
Net loss (in thousands) (129,422) (128,637) (131,289) (137,380) (142,310) (19,820) (89,445) (30,570) (76,086) (61,554) (47,104) (43,930) (3,175) (40,780) (39,405) (30,640) (29,573) (32,113) (29,366) (26,468) (22,017) (27,523) (30,281)
Earnings per share (EPS)2 -5.37 -5.62 -4.50 -4.09 -2.98 -2.29 -3.01 -2.54 -2.73 -1.87 -1.88 -1.79 -1.61 -1.99 -2.22 -2.05 -1.99 -1.87 -1.83 -1.94 0.00 0.00 0.00
Share price1, 3 36.32 31.70 39.44 43.11 37.75 51.82 38.06 35.02 41.10 31.82 24.23 18.73 16.94 21.51 15.76 14.86 11.19 13.51 9.01 6.01 7.12 7.10 8.70
Valuation Ratio
P/E ratio4 — — — — — — — — — — — — — — — — — — — — — — —
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 38.27 30.55 34.43 22.62 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82 — — — — — — —
Amgen Inc. 18.09 16.31 16.18 19.56 21.00 20.03 22.23 21.05 21.91 22.56 19.20 18.82 17.25 19.97 17.70 17.07 — — — — — — —
Bristol-Myers Squibb Co. 13.01 15.93 19.43 23.97 23.71 24.14 25.64 20.92 — — — — — — 144.77 41.99 — — — — — — —
Danaher Corp. 24.76 29.99 25.00 25.65 26.65 32.73 32.15 29.94 38.81 37.87 39.26 44.49 46.61 41.91 35.88 38.34 — — — — — — —
Eli Lilly & Co. 110.43 76.21 65.16 50.08 55.53 51.05 45.29 40.66 40.07 40.34 28.77 31.95 22.54 25.59 26.56 16.19 — — — — — — —
Gilead Sciences Inc. 17.10 17.88 17.75 22.68 29.30 18.66 17.25 12.36 11.44 16.83 277.25 641.48 59.19 — 19.58 16.45 — — — — — — —
Johnson & Johnson 10.12 33.35 33.43 22.97 23.52 24.98 23.95 20.93 23.98 25.51 28.35 28.92 22.51 25.68 23.06 25.99 — — — — — — —
Merck & Co. Inc. 56.85 86.53 22.92 19.21 16.41 13.36 15.70 14.78 28.65 34.23 28.00 26.72 17.67 19.70 19.18 20.60 — — — — — — —
Pfizer Inc. 16.60 9.42 7.44 7.58 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62 25.36 14.99 13.04 11.63 — — — — — — —
Regeneron Pharmaceuticals Inc. 22.35 19.48 19.77 19.68 14.98 11.67 9.15 8.37 9.96 10.38 13.27 15.09 19.91 22.27 28.35 19.86 — — — — — — —
Thermo Fisher Scientific Inc. 29.57 37.01 34.99 30.55 27.64 31.09 28.15 27.35 29.43 24.63 23.23 27.89 38.43 44.19 35.50 33.36 — — — — — — —
Zoetis Inc. 32.40 39.38 39.82 37.68 29.57 39.04 38.92 45.82 51.98 50.61 44.83 48.25 48.84 47.41 37.05 45.89 — — — — — — —

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
EPS = (Net lossQ3 2023 + Net lossQ2 2023 + Net lossQ1 2023 + Net lossQ4 2022) ÷ No. shares of common stock outstanding
= (-129,422,000 + -128,637,000 + -131,289,000 + -137,380,000) ÷ 98,053,647 = -5.37

3 Closing price as at the filing date of Cytokinetics Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/E ratio = Share price ÷ EPS
= 36.32 ÷ -5.37 = —

5 Click competitor name to see calculations.

Price to Operating Profit (P/OP)

Cytokinetics Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 98,053,647 95,997,998 95,640,600 95,161,391 94,631,001 94,144,097 85,652,213 84,856,037 83,882,953 83,512,670 71,738,143 71,110,576 70,779,023 70,504,701 59,469,525 59,450,437 59,081,899 58,678,894 57,721,286 54,888,369 54,710,900 54,627,997 54,197,546
Selected Financial Data (US$)
Operating income (loss) (in thousands) (122,265) (122,049) (124,473) (127,030) (108,441) (10,874) (77,857) (21,704) (69,201) (54,797) (40,611) (36,407) 5,184 (32,358) (30,362) (23,706) (23,927) (26,716) (24,518) (21,458) (17,914) (23,413) (26,131)
Operating profit per share2 -5.06 -5.02 -3.88 -3.41 -2.31 -1.91 -2.61 -2.20 -2.40 -1.52 -1.45 -1.32 -1.15 -1.57 -1.76 -1.66 -1.64 -1.54 -1.51 -1.62 0.00 0.00 0.00
Share price1, 3 36.32 31.70 39.44 43.11 37.75 51.82 38.06 35.02 41.10 31.82 24.23 18.73 16.94 21.51 15.76 14.86 11.19 13.51 9.01 6.01 7.12 7.10 8.70
Valuation Ratio
P/OP ratio4 — — — — — — — — — — — — — — — — — — — — — — —
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 16.55 15.26 16.15 14.78 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82 — — — — — — —
Amgen Inc. 15.45 13.71 14.25 13.40 14.89 14.08 15.88 16.24 16.73 17.48 15.26 14.96 13.82 15.84 14.22 13.84 — — — — — — —
Bristol-Myers Squibb Co. 14.14 16.24 17.09 18.29 17.79 18.62 20.32 19.84 — — — — 39.45 33.97 27.33 24.42 — — — — — — —
Danaher Corp. 21.77 26.02 21.31 20.97 20.71 25.91 26.48 25.14 32.12 30.83 32.62 36.91 46.28 43.09 35.22 34.47 — — — — — — —
Eli Lilly & Co. 93.27 69.42 59.60 43.88 46.48 39.20 36.49 35.70 37.21 42.01 31.17 32.66 22.98 25.58 24.82 27.08 — — — — — — —
Gilead Sciences Inc. 12.16 11.57 11.21 14.21 16.27 11.02 10.78 7.76 7.27 8.88 18.31 19.38 29.86 — 21.83 20.66 — — — — — — —
Johnson & Johnson 15.10 18.22 18.26 17.62 19.64 20.45 21.06 18.68 18.99 20.14 21.12 21.84 19.46 19.66 18.67 19.83 — — — — — — —
Merck & Co. Inc. 33.75 44.67 18.53 15.55 13.85 11.72 14.29 15.39 30.71 38.03 30.14 23.89 16.00 17.23 15.88 17.47 — — — — — — —
Pfizer Inc. 18.89 9.37 6.78 6.80 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12 22.27 22.17 17.42 14.36 — — — — — — —
Regeneron Pharmaceuticals Inc. 21.13 19.32 18.68 18.01 12.91 9.68 7.98 7.55 9.32 9.65 13.32 14.82 20.36 23.98 26.60 19.01 — — — — — — —
Thermo Fisher Scientific Inc. 25.59 31.55 29.54 25.30 21.43 23.99 21.84 21.07 23.87 19.77 18.53 22.81 31.49 36.59 28.44 26.84 — — — — — — —
Zoetis Inc. 24.60 29.66 29.07 27.31 21.67 28.91 28.81 33.82 38.47 36.90 32.33 35.22 36.65 36.24 28.78 35.00 — — — — — — —

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
Operating profit per share = (Operating income (loss)Q3 2023 + Operating income (loss)Q2 2023 + Operating income (loss)Q1 2023 + Operating income (loss)Q4 2022) ÷ No. shares of common stock outstanding
= (-122,265,000 + -122,049,000 + -124,473,000 + -127,030,000) ÷ 98,053,647 = -5.06

3 Closing price as at the filing date of Cytokinetics Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 36.32 ÷ -5.06 = —

5 Click competitor name to see calculations.

Price to Sales (P/S)

Cytokinetics Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 98,053,647 95,997,998 95,640,600 95,161,391 94,631,001 94,144,097 85,652,213 84,856,037 83,882,953 83,512,670 71,738,143 71,110,576 70,779,023 70,504,701 59,469,525 59,450,437 59,081,899 58,678,894 57,721,286 54,888,369 54,710,900 54,627,997 54,197,546
Selected Financial Data (US$)
Revenues (in thousands) 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
Sales per share2 0.08 0.10 1.03 0.99 1.57 1.61 0.76 0.83 0.26 0.69 0.82 0.79 0.77 0.27 0.37 0.45 0.53 0.61 0.60 0.57 0.00 0.00 0.00
Share price1, 3 36.32 31.70 39.44 43.11 37.75 51.82 38.06 35.02 41.10 31.82 24.23 18.73 16.94 21.51 15.76 14.86 11.19 13.51 9.01 6.01 7.12 7.10 8.70
Valuation Ratio
P/S ratio4 455.70 305.78 38.47 43.37 24.10 32.28 50.13 42.19 159.98 45.97 29.69 23.86 22.07 81.16 42.16 32.88 21.30 22.26 14.99 10.47 — — —
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 4.52 4.74 4.60 4.61 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22 — — — — — — —
Amgen Inc. 5.34 5.14 5.14 5.17 5.85 5.35 5.21 5.10 5.04 5.37 5.68 5.64 5.33 6.30 5.96 6.03 — — — — — — —
Bristol-Myers Squibb Co. 2.40 2.81 3.10 3.29 3.39 3.39 3.41 3.16 2.85 3.44 3.28 3.16 3.66 3.97 4.45 5.52 — — — — — — —
Danaher Corp. 5.13 6.48 5.76 5.79 5.66 6.59 6.68 6.37 7.91 7.72 7.27 7.01 8.15 7.48 6.34 6.29 — — — — — — —
Eli Lilly & Co. 17.18 16.78 13.38 10.96 11.46 9.99 9.47 8.01 8.62 9.16 6.88 8.06 5.41 6.26 6.36 6.03 — — — — — — —
Gilead Sciences Inc. 3.69 3.61 3.70 3.86 3.64 2.84 2.86 2.85 3.11 3.30 3.31 3.24 3.29 3.95 4.34 4.00 — — — — — — —
Johnson & Johnson 3.83 4.64 4.60 4.34 4.69 4.80 5.00 4.66 4.69 5.08 5.09 5.15 4.73 4.84 4.78 4.79 — — — — — — —
Merck & Co. Inc. 4.42 4.62 5.16 4.71 4.25 3.87 4.12 3.96 4.32 4.05 4.23 3.93 4.30 4.38 4.05 4.33 — — — — — — —
Pfizer Inc. 2.54 2.60 2.33 2.37 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50 4.71 4.69 4.21 3.66 — — — — — — —
Regeneron Pharmaceuticals Inc. 6.81 6.61 6.69 7.01 5.87 4.66 4.40 4.20 5.14 5.20 5.78 6.24 7.62 8.31 8.10 5.34 — — — — — — —
Thermo Fisher Scientific Inc. 4.05 4.87 4.81 4.73 4.40 5.40 5.20 5.39 6.45 5.54 5.13 5.52 6.58 6.24 5.08 4.83 — — — — — — —
Zoetis Inc. 8.83 10.60 10.19 9.86 7.63 10.21 10.23 12.00 13.53 13.03 11.34 11.84 12.42 12.09 9.42 11.00 — — — — — — —

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
Sales per share = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ No. shares of common stock outstanding
= (378,000 + 867,000 + 4,613,000 + 1,957,000) ÷ 98,053,647 = 0.08

3 Closing price as at the filing date of Cytokinetics Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 36.32 ÷ 0.08 = 455.70

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Cytokinetics Inc. P/S ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Price to Book Value (P/BV)

Cytokinetics Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 98,053,647 95,997,998 95,640,600 95,161,391 94,631,001 94,144,097 85,652,213 84,856,037 83,882,953 83,512,670 71,738,143 71,110,576 70,779,023 70,504,701 59,469,525 59,450,437 59,081,899 58,678,894 57,721,286 54,888,369 54,710,900 54,627,997 54,197,546
Selected Financial Data (US$)
Stockholders’ equity (deficit) (in thousands) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Book value per share (BVPS)2 -4.48 -3.47 -2.39 -1.13 -0.17 1.18 1.36 2.87 2.97 0.20 0.95 1.59 2.11 -1.11 -0.77 -0.18 -0.34 -0.08 0.06 0.47 0.95 1.38 1.84
Share price1, 3 36.32 31.70 39.44 43.11 37.75 51.82 38.06 35.02 41.10 31.82 24.23 18.73 16.94 21.51 15.76 14.86 11.19 13.51 9.01 6.01 7.12 7.10 8.70
Valuation Ratio
P/BV ratio4 — — — — — 43.79 28.04 12.19 13.84 161.16 25.62 11.75 8.01 — — — — — 154.23 12.72 7.48 5.16 4.73
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 20.61 20.62 19.68 15.52 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31 — — — — — — — — —
Amgen Inc. 17.87 19.19 23.95 35.01 39.30 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92 — — — —
Bristol-Myers Squibb Co. 3.72 3.97 4.46 4.88 4.85 4.90 5.07 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91 — — — —
Danaher Corp. 2.78 3.65 3.33 3.64 3.77 4.36 4.36 4.16 5.11 4.82 4.46 3.93 4.38 3.90 3.68 3.72 3.02 3.19 2.88 — — — —
Eli Lilly & Co. 49.10 44.75 33.11 29.36 33.27 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37 — — — —
Gilead Sciences Inc. 4.50 4.63 4.72 4.90 4.63 3.82 3.91 3.65 3.94 4.41 4.40 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83 — — — —
Johnson & Johnson 4.92 5.79 6.00 5.37 6.04 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39 — — — —
Merck & Co. Inc. 6.35 6.96 6.38 6.07 5.63 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31 — — — —
Pfizer Inc. 1.80 2.04 2.14 2.48 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84 — — — —
Regeneron Pharmaceuticals Inc. 3.58 3.49 3.52 3.77 3.75 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74 — — — —
Thermo Fisher Scientific Inc. 3.88 4.84 4.99 4.83 4.46 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56 4.16 4.15 3.83 4.02 — — — —
Zoetis Inc. 14.55 18.84 18.35 18.08 13.11 17.82 17.32 20.55 22.02 22.21 19.45 20.97 22.55 25.71 21.68 25.42 21.53 24.00 21.31 — — — —

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= -438,801,000 ÷ 98,053,647 = -4.48

3 Closing price as at the filing date of Cytokinetics Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 36.32 ÷ -4.48 = —

5 Click competitor name to see calculations.